{"url_path":"/sec/ehsi/10-q/2026/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-20","source_url":"https://www.sec.gov/Archives/edgar/data/1089815/0001437749-26-017934-index.html","accession_number":"0001437749-26-017934","cik":"0001089815","ticker":"EHSI","issuer_name":"Elite Health Systems Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1089815/0001437749-26-017934-index.html","primary_entity_key":"0001089815","primary_entity_name":"Elite Health Systems Inc."},"word_count":596,"has_tables":true,"body_markdown":"ehsi20260331_10q.htm\n\nQ1\n2026\n--12-31\nfalse\n0001089815\nfalse\nfalse\nfalse\nfalse\n0\n0\n0.01\n0.01\n\n00010898152026-01-012026-03-31\nthunderdome:item\niso4217:USD\n0001089815us-gaap:RelatedPartyMember2025-01-012025-12-31\n0001089815us-gaap:RelatedPartyMember2026-01-012026-03-31\nxbrli:shares\n0001089815us-gaap:RelatedPartyMembersrt:ChiefExecutiveOfficerMember2025-01-012025-12-31\n0001089815us-gaap:RelatedPartyMemberehsi:ExecutiveDirectorMember2025-01-012025-12-31\n0001089815us-gaap:RelatedPartyMemberehsi:PrincipalFinancialOfficerMember2025-01-012025-12-31\n0001089815us-gaap:RelatedPartyMemberehsi:BoardMembersMember2025-01-012025-12-31\n0001089815us-gaap:RelatedPartyMemberehsi:DirectorLeimkuhlerMember2025-01-012025-12-31\n0001089815us-gaap:RelatedPartyMemberehsi:DirectorStLawrenceMember2025-01-012025-12-31\niso4217:USDxbrli:shares\n0001089815us-gaap:RelatedPartyMember2025-12-31\n00010898152025-01-012025-12-31\n00010898152025-12-31\n0001089815ehsi:PhysicianSupportSystemsPSSMember2025-10-31\n0001089815ehsi:PhysicianSupportSystemsPSSMember2025-10-312025-10-31\nxbrli:pure\n00010898152025-01-012025-03-31\n00010898152026-03-31\nutr:Y\n00010898152025-10-31\n0001089815ehsi:CBOncologyPartnersCBOPMember2025-12-31\n0001089815ehsi:CBOncologyPartnersCBOPMember2026-03-31\n0001089815ehsi:CBOncologyPartnersCBOPMember2025-01-012025-03-31\n0001089815ehsi:CBOncologyPartnersCBOPMember2026-01-012026-03-31\n0001089815ehsi:CBOncologyPartnersCBOPMember2025-01-012025-03-31\n0001089815ehsi:CBOncologyPartnersCBOPMember2026-01-012026-03-31\n0001089815ehsi:CBOncologyPartnersCBOPMember2026-03-31\n0001089815ehsi:CBOncologyPartnersCBOPMember2024-01-012024-12-31\n0001089815ehsi:CBOncologyPartnersCBOPMember2025-01-012025-12-31\n00010898152025-03-31\n0001089815us-gaap:PrivatePlacementMember2023-11-272026-03-31\n00010898152024-01-012024-12-31\n0001089815ehsi:EliteHealthPlanIncMember2021-10-01\n00010898152024-12-31\n0001089815us-gaap:RetainedEarningsMember2026-03-31\n0001089815ehsi:StockToBeIssuedMember2026-03-31\n0001089815us-gaap:AdditionalPaidInCapitalMember2026-03-31\n0001089815us-gaap:CommonStockMember2026-03-31\n0001089815us-gaap:RetainedEarningsMember2026-01-012026-03-31\n0001089815us-gaap:AdditionalPaidInCapitalMember2026-01-012026-03-31\n0001089815us-gaap:CommonStockMember2026-01-012026-03-31\n0001089815us-gaap:RetainedEarningsMember2025-12-31\n0001089815ehsi:StockToBeIssuedMember2025-12-31\n0001089815us-gaap:AdditionalPaidInCapitalMember2025-12-31\n0001089815us-gaap:CommonStockMember2025-12-31\n0001089815us-gaap:RetainedEarningsMember2025-03-31\n0001089815ehsi:StockToBeIssuedMember2025-03-31\n0001089815us-gaap:AdditionalPaidInCapitalMember2025-03-31\n0001089815us-gaap:CommonStockMember2025-03-31\n0001089815us-gaap:AdditionalPaidInCapitalMember2025-01-012025-03-31\n0001089815us-gaap:CommonStockMember2025-01-012025-03-31\n0001089815ehsi:StockToBeIssuedMember2025-01-012025-03-31\n0001089815us-gaap:RetainedEarningsMember2024-12-31\n0001089815ehsi:StockToBeIssuedMember2024-12-31\n0001089815us-gaap:AdditionalPaidInCapitalMember2024-12-31\n0001089815us-gaap:CommonStockMember2024-12-31\n00010898152026-04-30\n0001089815ehsi:EliteHealthPlanIncMember2026-01-012026-03-31\n0001089815ehsi:PhysicianSupportSystemsPSSMember2026-01-012026-03-31\n\n \n\n \n\n[Table of Contents](#toc)\n\n \n\n**UNITED STATES**\n\n**SECURITIES AND EXCHANGE COMMISSION**\n\n**Washington, D.C. 20549**\n\n \n\n**FORM 10-Q**\n\n \n\n☒\n\nQUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934\n\n**For the quarterly period ended March 31, 2026**\n\nor\n\n☐\n\nTRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT\n\nFor the transition period from                to                .\n\n \n\nCommission file number: 0-15586\n\n \n\n**Elite Health Systems Inc.**\n\n(Exact name of registrant as specified in its charter)\n\n \n\n**Delaware**\n\n**47-5370333**\n\n(State or other jurisdiction of\n\n(I.R.S. Employer\n\nincorporation or organization)\n\nIdentification No.)\n\n \n\n**1131 W 6****th****Street, Ontario, CA 91762**\n\n(Address of principal executive offices)\n\n \n\n**(909) 657-2705**\n\n(Registrant's telephone number)\n\n \n\nSecurities registered pursuant to Section 12(b) of the Act: None\n\n \n\nSecurities registered pursuant to Section 12(g) of the Act: None\n\n \n\nIndicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.     Yes ☒       No ☐\n\n \n\nIndicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (Section 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).     Yes ☒       No ☐\n\n \n\nIndicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company, and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one):\n\nLarge accelerated filer     ☐\n\nAccelerated filer     ☐\n\nNon-accelerated filer     ☐\n\nSmaller reporting company     ☒\n\n \n\nEmerging Growth Company     ☐\n\n \n\nIf an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.    ☐\n\n \n\nIndicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes ☐         No ☒\n\n \n\nThe number of shares of the registrant’s common stock, $0.01 par value, outstanding as of April 30, 2026 was 28,521,620.\n\n \n\n1\n\n[Table of Contents](#toc)\n\n  \n\n \n\n**Table of Contents**\n\n \n\n[**PART I - FINANCIAL INFORMATION**](#partone)\n\n[3](#partone)\n\n[Item 1.  Financial Statements](#partone)\n\n[3](#partone)\n\n[Item 2.  Management Discussion and Analysis of Financial Condition and Results of Operations.](#item2)\n\n[16](#item2)\n\n[Item 3.  Quantitative and Qualitative Disclosures About Market Risk.](#item3)\n\n[19](#item3)\n\n[Item 4.  Controls and Procedures](#item4)\n\n[19](#item4)\n\n[**PART II**–** OTHER INFORMATION**](#parttwo)\n\n[21](#parttwo)\n\n[Item 1.  Legal Proceedings](#legal)\n\n[21](#legal)\n\n[Item 2.  Unregistered Sales of Equity Securities, Use of Proceeds, and Issuer Purchases of Equity Securities Unregistered Sales of Equity Securities and Use of Proceeds](#securities)\n\n[21](#securities)\n\n[Item 3.  Defaults Upon Senior Securities](#defaults)\n\n[21](#defaults)\n\n[Item 4.  Submission of Matters to a Vote of Security Holders](#submission)\n\n[21](#submission)\n\n[Item 5.  Other Information](#other)\n\n[21](#other)\n\n[Item 6.  Exhibits](#exhibits)\n\n[21](#exhibits)\n\n[**SIGNATURES**](#sigs)\n\n[22](#sigs)\n\n \n\n2\n\n[Table of Contents](#toc)\n\n  \n\n \n\n \n\n**PART I - FINANCIAL INFORMATION**"}